Trius Therapeutics Reports 2012 Second Quarter Financial Results
06. August 2012 16:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Aug. 6, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius Therapeutics Commends Congressional Approval of Incentives to Develop Innovative Antibiotics
27. Juni 2012 08:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, June 27, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today commented on the approval by the United States Congress of the Prescription Drug Users Fee Act (PDUFA V) which...
Trius Therapeutics Added to the NASDAQ Biotechnology Index
14. Mai 2012 08:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, May 14, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius Therapeutics Reports First Quarter 2012 Financial Results
08. Mai 2012 16:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, May 8, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for...
Trius to Present at May Investor Conferences
07. Mai 2012 16:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, May 7, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a...
Trius to Present at the BioCentury Future Leaders Conference
16. April 2012 08:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, April 16, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will...
Trius' Antibiotic Tedizolid Demonstrates High Efficacy in Patients With Cellulitis
02. April 2012 07:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, April 2, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the results of a subgroup analysis from its first Phase 3 investigational study (TR701-112 Trial) in...
Trius Therapeutics Reports Fourth Quarter and Year End 2011 Financial Results
13. März 2012 08:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, March 13, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius to Present at Citi & RBC Investor Conferences
23. Februar 2012 07:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Feb. 23, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...
Trius Announces Issuance of Tedizolid Patent in China
16. Februar 2012 07:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the issuance of Patent # 908206 by the State Intellectual Property Office of the People's Republic...